Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IPSC Hot Sheet
Join SI Premium – FREE
Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11).
For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptiv (APTV) Tops Q3 EPS by 9c; offers guidance
- Stevanato Group S.p.A. (STVN) Reports In-Line Q3 EPS
- Dynatrace Inc. (DT) Tops Q2 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
